Therapeutic aims of drugs offering only progression-free survival are misunderstood by patients, and oncologists may be overly optimistic about likely benefits
Crossref DOI link: https://doi.org/10.1007/s00520-016-3408-7
Published Online: 2016-09-13
Published Print: 2017-01
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Fallowfield, L. J.
Catt, S. L.
May, S. F.
Matthews, L.
Shilling, V. M.
Simcock, R.
Westwell, S.
Jenkins, V. A.
Funding for this research was provided by:
Boehringer Ingelheim International GmbH (G1002)
License valid from 2016-09-13